...
首页> 外文期刊>Neuro-Oncology >Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
【24h】

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients

机译:优化资格标准和临床试验,以提高原发性脑肿瘤患者的临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

Building on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.
机译:建立倡议,提高临床试验参与涉及神经肿瘤学会的临床试验,神经肿瘤学工作组的反应评估,患者倡导群体,临床试验合作团体和其他合作伙伴,我们评估了资格标准和审判行为的影响论神经肿瘤临床试验参与。临床试验往往载有前后研究的资格标准,可能是过度限制性和不必要的,不必要的,无需限制患者应计。应基于研究的目标和设计来评估包含和排除标准,以及它们是否影响患者安全性和/或治疗疗效。此外,我们还评估临床试验,作为障碍的障碍,讨论最小化神经肿瘤学试验的障碍的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号